This immunization approach markedly activates protective immunity against replicable MC38 tumor cells challenge, leading to significant inhibition of tumor growth and a marked increase in the infiltration of CD8+ T cells in the tumor microenvironment. The gene discussed is CD8A; the disease is neoplasm.